Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers

Copyright © 2018 Pfizer Inc. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 191(2018) vom: 15. Juni, Seite 10-20
1. Verfasser: Weinhold, Kent J (VerfasserIn)
Weitere Verfasser: Bukowski, Jack F, Brennan, Todd V, Noveck, Robert J, Staats, Janet S, Lin, Liwen, Stempora, Linda, Hammond, Constance, Wouters, Ann, Mojcik, Christopher F, Cheng, John, Collinge, Mark, Jesson, Michael I, Hazra, Anasuya, Biswas, Pinaki, Lan, Shuping, Clark, James D, Hodge, Jennifer A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't Cytotoxicity Healthy volunteers Interferon-γ Natural killer cells T cells Tofacitinib Janus Kinase Inhibitors mehr... Piperidines Pyrimidines Pyrroles tofacitinib 87LA6FU830
Online verfügbar Volltext